HK1140141A1 - Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer - Google Patents

Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Info

Publication number
HK1140141A1
HK1140141A1 HK10106504.4A HK10106504A HK1140141A1 HK 1140141 A1 HK1140141 A1 HK 1140141A1 HK 10106504 A HK10106504 A HK 10106504A HK 1140141 A1 HK1140141 A1 HK 1140141A1
Authority
HK
Hong Kong
Prior art keywords
cancer
pi3k
alpha
treatment
combination therapies
Prior art date
Application number
HK10106504.4A
Other languages
English (en)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of HK1140141A1 publication Critical patent/HK1140141A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK10106504.4A 2007-04-11 2010-07-05 Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer HK1140141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11
PCT/US2008/004570 WO2008127594A2 (en) 2007-04-11 2008-04-08 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1140141A1 true HK1140141A1 (en) 2010-10-08

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10106504.4A HK1140141A1 (en) 2007-04-11 2010-07-05 Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Country Status (34)

Country Link
US (1) US8481001B2 (ru)
EP (1) EP2139483B9 (ru)
JP (2) JP5726515B2 (ru)
KR (1) KR101586774B1 (ru)
CN (2) CN101959516B (ru)
AU (1) AU2008239668B2 (ru)
BR (1) BRPI0810208A2 (ru)
CA (1) CA2684056A1 (ru)
CO (1) CO6140024A2 (ru)
CR (1) CR11099A (ru)
CY (1) CY1114608T1 (ru)
DK (1) DK2139483T3 (ru)
EA (1) EA019064B1 (ru)
EC (1) ECSP099723A (ru)
ES (1) ES2438998T3 (ru)
GT (1) GT200900263A (ru)
HK (1) HK1140141A1 (ru)
HR (1) HRP20131081T1 (ru)
IL (1) IL201211A (ru)
MA (1) MA31335B1 (ru)
ME (1) ME00937B (ru)
MX (1) MX2009010929A (ru)
MY (1) MY150797A (ru)
NI (1) NI200900184A (ru)
NZ (1) NZ580009A (ru)
PL (1) PL2139483T3 (ru)
PT (1) PT2139483E (ru)
RS (1) RS53020B (ru)
SI (1) SI2139483T1 (ru)
SV (1) SV2009003390A (ru)
TN (1) TN2009000399A1 (ru)
UA (1) UA98141C2 (ru)
WO (1) WO2008127594A2 (ru)
ZA (1) ZA200906765B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594628A (en) * 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
CA2623768C (en) * 2005-10-07 2016-04-12 Exelixis, Inc. N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
SI2139484T1 (sl) * 2007-04-10 2013-10-30 Exelixis, Inc. Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji
EP2374802B1 (en) * 2008-11-10 2014-04-23 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
EA201390085A1 (ru) 2010-07-09 2013-06-28 Экселиксис, Инк. Композиции ингибиторов киназ для лечения рака
US9670212B2 (en) 2010-09-14 2017-06-06 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
AU2011317675A1 (en) 2010-10-20 2013-05-02 Merck Serono S.A. Geneva Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)sulfonamides
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
AU2012308414A1 (en) * 2011-09-14 2014-05-01 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
EP2763994A4 (en) * 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
SG11201400543TA (en) * 2011-10-28 2014-08-28 Novartis Ag Method of treating gastrointestinal stromal tumors
US20140303172A1 (en) * 2011-11-01 2014-10-09 Exelixis, Inc. Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
EP2797628A4 (en) 2011-12-27 2015-07-29 Kadmon Corp Llc METHODS OF TREATING BREAST CANCER NOT RESPONDING TO TRASTUZUMAB
JP6077642B2 (ja) 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
EP2882722B1 (en) 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as gpr6 modulators
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
JP6139789B2 (ja) 2013-10-16 2017-05-31 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合複素環化合物、その調製方法、医薬組成物及びその使用
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276527A1 (en) * 2003-01-17 2006-12-07 Thresold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
BRPI0615233A2 (pt) * 2005-08-26 2011-05-10 Serono Lab derivados de pirazina e uso dos mesmos como inibidores p13k
CA2623768C (en) 2005-10-07 2016-04-12 Exelixis, Inc. N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
NZ594628A (en) 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
BRPI0808013A2 (pt) 2007-02-22 2014-06-17 Merck Serono Sa Compostos de quinoxalina e uso dos mesmos
SI2139484T1 (sl) 2007-04-10 2013-10-30 Exelixis, Inc. Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
AU2008239668A1 (en) 2008-10-23
EP2139483A2 (en) 2010-01-06
HRP20131081T1 (hr) 2013-12-20
EP2139483B9 (en) 2014-05-21
UA98141C2 (ru) 2012-04-25
EP2139483B1 (en) 2013-09-18
US8481001B2 (en) 2013-07-09
KR20100019436A (ko) 2010-02-18
JP5726515B2 (ja) 2015-06-03
GT200900263A (es) 2014-01-15
DK2139483T3 (da) 2014-01-13
BRPI0810208A2 (pt) 2014-10-21
ES2438998T3 (es) 2014-01-21
PL2139483T3 (pl) 2014-02-28
ME00937B (me) 2012-06-20
MX2009010929A (es) 2010-01-20
SV2009003390A (es) 2010-05-21
ZA200906765B (en) 2010-05-26
CY1114608T1 (el) 2016-10-05
JP2014074031A (ja) 2014-04-24
CR11099A (es) 2010-01-19
MY150797A (en) 2014-02-28
RS53020B (en) 2014-04-30
US20110123434A1 (en) 2011-05-26
JP2010523669A (ja) 2010-07-15
AU2008239668B2 (en) 2013-11-07
EA200970935A1 (ru) 2010-04-30
NZ580009A (en) 2012-06-29
CA2684056A1 (en) 2008-10-23
MA31335B1 (fr) 2010-04-01
CN103202842A (zh) 2013-07-17
WO2008127594A3 (en) 2009-04-30
CN101959516A (zh) 2011-01-26
TN2009000399A1 (fr) 2010-12-31
SI2139483T1 (sl) 2013-11-29
EA019064B1 (ru) 2013-12-30
IL201211A (en) 2015-09-24
PT2139483E (pt) 2013-12-27
IL201211A0 (en) 2010-05-31
WO2008127594A2 (en) 2008-10-23
CN101959516B (zh) 2013-05-08
KR101586774B1 (ko) 2016-01-19
NI200900184A (es) 2011-09-08
CO6140024A2 (es) 2010-03-19
ECSP099723A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
HK1140141A1 (en) Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
TN2012000622A1 (en) Combinations of kinase inhibitors for the treatment of cancer
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TW200738725A (en) Unsaturated mTOR inhibitors
MX2009009786A (es) Inhibidores de la via de hedgehog.
TW200722083A (en) Combinations and methods of using an indolinone compound
MX2013011332A (es) Combinaciones de compuestos inhibidores de akt y vemurafenib y metodos de uso de los mismos.
TN2011000298A1 (en) Compounds useful for inhibiting chk1
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
MX2009006574A (es) Tratamiento de cancer de pulmon.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
EA200870454A1 (ru) Способ ингибирования c-kit киназы
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
IN2012DN02816A (ru)
WO2007136615A3 (en) Combination cancer therapy
WO2012075472A3 (en) Chemical entities and therapeutic uses thereof
WO2008015538A3 (en) Use of diaza- and thiaza-cycloalkanediones for preventing and/or treating pain and /or migraine
CY1114609T1 (el) Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας αναστολεις p13k αλφα με βαση πυριδοπυριμιδινονη
UA99612C2 (en) Inhibitors of the hedgehog pathway

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210412